vascular endothelial growth factor

Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Investigational drug Luminate targets integrin receptorsAnti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
Topical drug delivery via mucus-penetrating particles blocks VEGF signalingA topical receptor tyrosine kinase inhibitor may be a potential noninvasive inhibitor of vascular endothelial growth factor signaling.